Rifabutin‐based High‐dose Proton‐pump Inhibitor and Amoxicillin Triple Regimen as the Rescue treatment for <i>Helicobacter pylori</i>

Abstract

Rifabutin-based high-dose proton-pump inhibitor (PPI)-combined therapy as empirical rescue treatment is more effective than standard dose PPI-combined rifabutin-based therapy, safe and best tolerable in third-line therapy in the Korean population. The key to successful rescue therapy with rifabutin-amoxicillin-PPI regimen may be to increase doses of PPI.